Memorial Sloan Kettering Cancer Center

Alan Ho, MD, PhD, presented updated phase II trial results of HPV16-targeted immunotherapeutic agent eseba-vec and PD-1 inhibitor pembrolizumab for HPV16-positive relapsed or metastatic head and neck squamous cell carcinoma at the 2024 SITC Annual Meeting. The study showed a 52% overall response rate and 80% disease control rate in 27 patients with PD-L1 CPS ≥ 20, with preliminary median progression-free survival over 16 months and a 12-month overall survival rate of 83%. The regimen demonstrated a manageable safety profile.

A high-fiber diet may prevent multiple myeloma in high-risk MGUS patients, according to a study presented at the American Society of Hematology meeting. The 12-week plant-based diet, rich in fruits, vegetables, beans, seeds, and whole grains, led to weight loss, improved insulin resistance, and a healthier gut microbiome, potentially slowing MGUS progression.

Five-year results confirm Polivy combination therapy as new standard of care for aggressive lymphoma, showing positive trend in overall survival and fewer subsequent treatments needed.

Five-year results confirm Polivy combination therapy as new standard of care for first-line DLBCL, showing positive trend in overall survival and fewer subsequent treatments needed.

Five-year follow-up of POLARIX study shows positive trend in overall survival for Polivy + R-CHP in first-line DLBCL, fewer subsequent treatments needed, and maintained benefits in progression-free and disease-free survival.

AbbVie announced updated results from the Phase 1b/2 EPCORE NHL-2 trial, showing 96% overall response rate (ORR) and 87% complete response (CR) rate in adult patients with relapsed or refractory follicular lymphoma (FL) treated with epcoritamab + lenalidomide + rituximab (R2). The data highlight the potential benefits of epcoritamab in combination with R2 as a strong and durable treatment option for FL.

New results from the Phase 1b/2 EPCORE NHL-2 trial show 96% overall response rate, 87% complete response, and 80% 21-month progression-free survival in patients with relapsed or refractory follicular lymphoma treated with epcoritamab plus lenalidomide + rituximab (R2). The study also reported a two-year overall survival rate of 90%. These findings support the ongoing Phase 3 EPCORE FL-1 trial and follow the recent breakthrough therapy designation granted by the FDA.

Epcoritamab (DuoBody® CD3xCD20) + lenalidomide + rituximab (R²) in R/R FL showed 96% ORR and 87% CR rate in a Phase 1b/2 trial with 111 patients, presented at ASH 2024.

AbbVie announced updated results from the Phase 1b/2 EPCORE NHL-2 trial, showing 96% overall response rate (ORR) and 87% complete response (CR) rate in adult patients with relapsed or refractory follicular lymphoma (FL) treated with epcoritamab + lenalidomide + rituximab (R2). The data were presented at the 66th Annual Meeting of the American Society of Hematology (ASH).